Meyka Pro banner
Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) AI-Powered Stock Analysis

See how Orchestra BioMed Holdings, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

OBIONASDAQ
HealthcareBiotechnology
$3.82
$0.08(2.14%)
U.S. Market opens in 14h 35m

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) AI-Powered Stock Analysis

See how Orchestra BioMed Holdings, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) Stock Overall Grade

Orchestra BioMed Holdings, Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

Z

Grade Breakdown by Metric

See how each financial and market factor contributes to Orchestra BioMed Holdings, Inc.'s overall NASDAQ stock rating.

Forecast

C+

Score

53/100

Financial Growth

C

Score

40/100

Fundamental Growth

C

Score

48/100

Key Ratios

C+

Score

52/100

Sector Comparison

B

Score

65/100

Industry Comparison

C+

Score

50/100

S&P 500 Benchmark

A+

Score

97/100

Analyst Consensus

C+

Score

50/100

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) AI-Powered Stock Analysis

On the NASDAQ, OBIO demonstrates Normal performance with an overall Forecast Score of 53/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (52/100, C+) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests Moderate divergence in outlook.

(NASDAQ: OBIO) Component Analysis Explained

Understand the key factors behind each Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions